The role of protease-activated receptor-1 in bone healing.
Shu Jun Song, Charles N Pagel, Therese M Campbell...
https://pubmed.ncbi.nlm.nih.gov/15743797/Actively Recruiting
Led by Arkansas Children's Hospital Research Institute · Updated on 2026-10-05
50
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are evaluating bone health in adult males with severe hemophilia A who are receiving long-term prophylaxis therapy. This observational study compares the effects of two treatments, emicizumab and efanesoctocog alfa, on bone mineral density and related biomarkers over a five-year period. The goal is to understand how these different therapies might influence bone remodeling and joint health in this population. Participants receive their usual prophylaxis treatment with either efanesoctocog alfa or emicizumab as part of routine clinical care. The study involves regular assessments including dual-energy X-ray absorptiometry DEXA scans to measure bone mineral density, blood tests to evaluate bone remodeling biomarkers, thrombin and plasmin generation, and joint health evaluations. These assessments occur annually throughout the five years of follow-up. During the study, participants are asked to undergo scheduled DEXA scans and provide blood samples at baseline and yearly for five years. They also complete standard bleeding and treatment logs to monitor health outcomes. Researchers will track changes in bone density at various sites including the femoral neck, lumbar spine, and total hip, along with biomarkers and coagulation parameters. The study includes ongoing monitoring to evaluate bone health outcomes associated with the different prophylactic therapies over the long term.
CONDITIONS
A Prospective Assessment of Bone Health in Patients With Severe Hemophilia A on Factor VIII vs Factor Mimetic Prophylaxis (Efa Emi Bone Health Study)
C
Carol D Pierce, RN
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Arkansas Children's Hospital Research Institute
Lead Sponsor
Genzyme, a Sanofi Company
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 5 years
Participants continue their routine prophylaxis treatment and undergo annual DEXA scans and blood tests to assess bone mineral density, bone remodeling biomarkers, thrombin and plasmin generation, and joint health over five years.
Annual visits
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Shu Jun Song, Charles N Pagel, Therese M Campbell...
https://pubmed.ncbi.nlm.nih.gov/15743797/T A Wallny, D T Scholz, J Oldenburg...
https://pubmed.ncbi.nlm.nih.gov/17212729/I R Walker, J A Julian
https://pubmed.ncbi.nlm.nih.gov/9873876/S Sivagurunathan, C N Pagel, L H Loh...
https://pubmed.ncbi.nlm.nih.gov/23419317/C Smit, F R Rosendaal, I Varekamp...
https://pubmed.ncbi.nlm.nih.gov/2493872/Andrew D Bunta
https://pubmed.ncbi.nlm.nih.gov/21847769/Charles N Pagel, Michael R de Niese, Linda A Abraham...
https://pubmed.ncbi.nlm.nih.gov/14555279/Galen Goldscheitter, Michael Recht, Paul Sochacki...
https://pubmed.ncbi.nlm.nih.gov/32856388/Kanjaksha Ghosh, Shrimati Shetty
https://pubmed.ncbi.nlm.nih.gov/22587752/G Gerstner, M L Damiano, A Tom...
https://pubmed.ncbi.nlm.nih.gov/19187193/Arkansas Children's Hospital Research Institute
Lead Sponsor
Genzyme, a Sanofi Company
Collaborating Sponsor